Thousands of South Africans are suffering from preventable disability from autoimmune diseases that could be effectively treated if diagnosed early, but systemic delays in recognition and specialist access are turning manageable conditions into life-altering complications, writes Sipho Ntshalintshali for News24.
Ntshalintshali pwrites:
There is a quiet pattern unfolding across clinics in South Africa, one that rarely makes headlines, yet shapes the lives of thousands of patients. It begins with symptoms that seem ordinary: persistent joint pain, unexplained fatigue, intermittent swelling, or a rash that comes and goes. Patients seek help, often more than once. They are treated symptomatically, reassured, and sent home.
Months pass. Sometimes years. By the time a diagnosis is finally made, the disease has already declared itself through joint deformities, kidney damage, or irreversible organ involvement.
This is the reality of autoimmune disease in much of Africa. Autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, and vasculitis, are not rare. They are chronic, often systemic diseases in which the immune system mistakenly attacks the body’s own tissues. What makes them particularly challenging is not only their complexity, but the subtlety with which they begin.
A missed window
In high-resource settings, early recognition and prompt treatment have transformed outcomes. Many autoimmune diseases, once considered relentlessly progressive, can now be controlled, and in some cases effectively driven into remission through modern therapies.
The window for this success, however, is narrow. It depends on early diagnosis. In our setting, that window is too often missed.
A central issue is awareness, both among patients and within the healthcare system itself.
For many patients, the early symptoms of autoimmune disease are not recognised as serious. Chronic pain may be normalised, particularly in communities where access to healthcare is limited or where daily survival takes precedence. Fatigue is dismissed. Swelling is endured. By the time care is sought, the disease has often progressed significantly.
Equally concerning is the gap in recognition at the primary healthcare level.
Primary care clinicians are the first point of contact for the majority of South Africans. They carry an immense burden, managing a wide spectrum of conditions with limited resources.
In this environment, autoimmune diseases are often complex, multi-system, and require a high index of suspicion that can be difficult to identify early. Yet this is precisely where the greatest opportunity lies.
If autoimmune diseases are recognised at the primary care level, referred appropriately, and treated early, outcomes can be dramatically improved.
The concept of a “window of opportunity” in diseases such as rheumatoid arthritis is well established: initiate treatment early, and irreversible damage can be prevented. Miss that window, and even the most advanced therapies cannot fully reverse what has been lost.
Not that these diseases are untreatable, but that they are treated too late. The consequences extend beyond individual patients. Disability from autoimmune disease affects families, communities, and the broader economy. Individuals in their most productive years may lose the ability to work, care for their families, or participate fully in society.
Scarcity of rheumatologists
Another critical challenge is the scarcity of rheumatologists. In South Africa, as in many developing countries, the number of trained rheumatologists is far below what is required to meet the population’s needs. Specialists are concentrated in urban centres, leaving vast areas underserved. Patients in rural and peri-urban settings often face long delays before accessing specialist care, if they reach it at all.
This shortage is not merely a workforce issue; it is a strategic priority. If we are to address the burden of autoimmune disease, training in rheumatology must be strengthened.
Universities and training institutions need to prioritise the development of specialists in this field, while also equipping generalists and primary care clinicians with the skills to recognise and initiate early management of these conditions.
Encouragingly, efforts are under way at both global and continental levels to address these gaps. The International League of Associations for Rheumatology (ILAR) has placed increasing emphasis on global awareness, education, and capacity-building, particularly in low- and middle-income countries. Its vision recognises that advances in rheumatology must reach beyond well-resourced settings if they are to have meaningful global impact.
Within Africa, the African League Against Rheumatism (AFLAR) plays a pivotal role. AFLAR is actively raising awareness, promoting education, and supporting research tailored to the unique challenges of autoimmune disease on the continent. These efforts are essential in building a sustainable framework for rheumatology care in Africa.
However, organisations alone cannot change outcomes without broader engagement.
Need for innovation
We need a shift in how autoimmune disease is perceived by the public, by healthcare systems, and by policymakers. Awareness campaigns must extend beyond specialist circles into communities and primary care settings. Educational initiatives should empower clinicians to recognise early warning signs and act decisively.
Innovation also has a role to play. Emerging diagnostic tools, including point-of-care technologies, hold promise in bridging the gap between primary care and specialist services. These innovations could enable earlier detection in settings where access to advanced diagnostics is limited.
But ultimately, the solution lies in alignment between awareness, education, workforce development, and health system strengthening.
As clinicians, we are often confronted with the consequences of delay. We see what happens when the diagnosis comes too late. We manage complications that could have been prevented. And we have difficult conversations with patients about damage that cannot be undone. It is in these moments that the true cost of inaction becomes clear.
Autoimmune diseases are no longer conditions we cannot treat. The challenge now is ensuring that we treat them in time.
Dr Sipho Ntshalintshali is a Rheumatologist at Grey’s Hospital in KZN.
See more from MedicalBrief archives:
Chronic shortage of rheumatologists in SA
Shortage of sub-specialist posts increases healthcare risks
Africa’s medical specialist shortage at critical point – experts
Vitamin D and Omega-3 supplementation reduced autoimmune disease – VITAL trial